164 related articles for article (PubMed ID: 3966729)
1. The second-generation sulfonylureas: change or progress?
Kreisberg RA
Ann Intern Med; 1985 Jan; 102(1):125-6. PubMed ID: 3966729
[No Abstract] [Full Text] [Related]
2. Sulfonylureas.
Zimmerman BR
Endocrinol Metab Clin North Am; 1997 Sep; 26(3):511-22. PubMed ID: 9314012
[TBL] [Abstract][Full Text] [Related]
3. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
4. Sulfonylurea treatment in type 2 diabetes.
Bester K; Ton J; Korownyk C
Can Fam Physician; 2018 Apr; 64(4):295. PubMed ID: 29650607
[No Abstract] [Full Text] [Related]
5. Newer Sulfonylureas Not Associated with Increased Mortality, MIs, or Strokes.
Barry HC
Am Fam Physician; 2016 Sep; 94(5):386. PubMed ID: 27583428
[No Abstract] [Full Text] [Related]
6. Is it time to ban sulfonylureas?
Ceriello A
J Diabetes; 2020 Nov; 12(11):848-850. PubMed ID: 32767650
[No Abstract] [Full Text] [Related]
7. [Will DPP-4 inhibitors replace sulfonylureas in the treatment of type 2 diabetes? Pro].
Nauck MA
Dtsch Med Wochenschr; 2011 Mar; 136(11):546. PubMed ID: 21351041
[No Abstract] [Full Text] [Related]
8. Glimepiride for NIDDM.
Med Lett Drugs Ther; 1996 May; 38(975):47-8. PubMed ID: 8632731
[No Abstract] [Full Text] [Related]
9. Are sulfonylureas passé?
Green JB; Feinglos MN
Curr Diab Rep; 2006 Nov; 6(5):373-7. PubMed ID: 17076998
[TBL] [Abstract][Full Text] [Related]
10. Sulphonylureas in the treatment of non-insulin-dependent diabetes.
Ferner RE; Alberti KG
Q J Med; 1989 Nov; 73(271):987-95. PubMed ID: 2695959
[No Abstract] [Full Text] [Related]
11. Neuroglycopenic Seizures: Sulfonylureas, Sulfamethoxazole, or Both?
Khan U; Seetharaman S; Merchant R
Am J Med; 2017 Jan; 130(1):e29-e30. PubMed ID: 27593606
[No Abstract] [Full Text] [Related]
12. The place of sulfonylureas in the therapy for type 2 diabetes mellitus.
Del Prato S; Pulizzi N
Metabolism; 2006 May; 55(5 Suppl 1):S20-7. PubMed ID: 16631807
[TBL] [Abstract][Full Text] [Related]
13. Oral hypoglycemic agents in type II diabetes mellitus.
Lubbos H; Miller JL; Rose LI
Am Fam Physician; 1995 Nov; 52(7):2075-8. PubMed ID: 7484707
[TBL] [Abstract][Full Text] [Related]
14. [Risk and benefit of sulfonylureas--their role in view of new treatment options for type 2 diabetes].
Rustenbeck I
Med Monatsschr Pharm; 2016 Feb; 39(2):65-72; quiz 73-4. PubMed ID: 26983335
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone/glimepiride (Avandaryl) for diabetes.
Med Lett Drugs Ther; 2006 Mar; 48(1230):22-4. PubMed ID: 16538189
[No Abstract] [Full Text] [Related]
16. Sulfonylureas and mortality in diabetic patients after myocardial infarction.
Brady PA; Al-Suwaidi J; Kopecky SL; Terzic A
Circulation; 1998 Feb; 97(7):709-10. PubMed ID: 9495313
[No Abstract] [Full Text] [Related]
17. Pioglitazone + glimepiride: a combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):145. PubMed ID: 17724836
[No Abstract] [Full Text] [Related]
18. Pioglitazone/glimepiride (Duetact) for diabetes.
Med Lett Drugs Ther; 2007 Jan; 49(1253):9-11. PubMed ID: 17261966
[No Abstract] [Full Text] [Related]
19. Rosiglitazone + glimepiride: new drug. Another combination product to avoid.
Prescrire Int; 2007 Aug; 16(90):144. PubMed ID: 17726795
[No Abstract] [Full Text] [Related]
20. Possible risk of sulphonylureas in the treatment of non-insulin-dependent diabetes mellitus and coronary artery disease.
Fasching P
Diabetologia; 1998 Jun; 41(6):743-4. PubMed ID: 9662063
[No Abstract] [Full Text] [Related]
[Next] [New Search]
